28558-00-1 Usage
Uses
Used in Pharmaceutical Industry:
(6alpha,11beta,17beta)-11,17-dihydroxy-6-methylandrost-4-en-3-one is used as a precursor for the synthesis of sex hormones like testosterone and estrogen for the treatment of various hormonal imbalances and conditions related to sexual development and function.
Used in Research and Development:
This chemical is used as a research compound for studying the effects of steroid hormones on immune function, energy metabolism, and stress response. It aids in understanding the role of these hormones in the development and maintenance of reproductive tissues and sexual characteristics.
Used in Therapeutic Applications:
(6alpha,11beta,17beta)-11,17-dihydroxy-6-methylandrost-4-en-3-one is used as a potential therapeutic agent for conditions such as aging, obesity, and autoimmune diseases due to its involvement in various physiological processes and its precursor role in the production of sex hormones.
Check Digit Verification of cas no
The CAS Registry Mumber 28558-00-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,5,5 and 8 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 28558-00:
(7*2)+(6*8)+(5*5)+(4*5)+(3*8)+(2*0)+(1*0)=131
131 % 10 = 1
So 28558-00-1 is a valid CAS Registry Number.
28558-00-1Relevant academic research and scientific papers
ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT
-
, (2008/06/13)
The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.
TRANSDERMAL ADMINISTRATION OF MENT
-
, (2008/06/13)
The present invention relates to transdermal dosage forms for delivery of androgens.
Method for androgen supplementation
-
, (2008/06/13)
A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.
